Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech. Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.
Milestone:
We are now entering Phase II of our study
Market:
≥ 595 Millions of people have OA in the world (Kloppenburg et al., 2020). Estimated sales per year: 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)